Related Experiment Video
Updated: Feb 6, 2026

Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
Published on: May 24, 2016
Toxicities with targeted therapies after immunotherapy in metastatic melanoma
Nicole Grogan1, Umang Swami2, Aaron D Bossler3
1Departments of Internal Medicine.
Abstract:
Over the last decade, melanoma treatment has taken rapid strides with the advent of immunotherapies and targeted agents. With these new agents, there has been a significant improvement in patient survival. However, these new treatment options may sometimes lead to unanticipated side effects that make these treatments challenging to administer and monitor. In preclinical studies, BRAF and MEK inhibitors have shown to modulate tumor microenvironment and potentiate immunotherapies. Therefore, some patients who had prior treatment with immunotherapies can develop immune toxicities even with these targeted agents due to the long half-life of these monoclonal antibodies. Herein, we present our institutional experience with regard to these unexpected toxicities with targeted agents in patients who had previous treatment with immunotherapies. This case series lays out the various side effects along with details of their management, outcomes, and patient response.
Insights
Melanoma treatments like immunotherapy and targeted agents improve survival but can cause unexpected immune toxicities. This study details these side effects in patients previously treated with immunotherapy, offering insights into management and outcomes.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Melanoma treatment has advanced with immunotherapies and targeted agents, improving patient survival.
- These novel therapies can present unique challenges due to potential side effects.
- Preclinical data suggest BRAF and MEK inhibitors may interact with immunotherapies.
Observation:
- Patients previously treated with immunotherapy may experience immune toxicities when subsequently treated with targeted agents.
- The long half-life of monoclonal antibodies in immunotherapy can contribute to these delayed toxicities.
Findings:
- This case series presents institutional experience with unexpected immune toxicities associated with targeted agents in melanoma patients with prior immunotherapy exposure.
- Detailed side effects, management strategies, patient outcomes, and responses are outlined.
Implications:
- Understanding and managing these immune toxicities is crucial for optimizing combined treatment strategies in melanoma.
- Further research into the mechanisms and predictive factors for these toxicities is warranted to improve patient care.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Gene Therapy
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Group Therapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

